Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202 Woyach, J. A., Ruppert, A. S., Heerema, N. A., Zhao, W., Booth, A. M., Ding, W., Bartlett, N. L., Brander, D. M., Barr, P., Rogers, K. A., Parikh, S. A., Coutre, S., Hurria, A., Lozanski, G., Nattam, S., Larson, R. A., Erba, H. P., Litzow, M. R., Owen, C., Atkins, J., Abramson, J. S., Little, R. F., Smith, S. E., Stone, R. M., Mandrekar, S. J., Byrd, J. C. AMER SOC HEMATOLOGY. 2018

View details for DOI 10.1182/blood-2018-99-116653

View details for Web of Science ID 000454837600060